Pregnancy and Child Health Research Center, HealthPartners Institute, Minneapolis, Minnesota, USA.
Center for Evaluation and Survey Research, HealthPartners Institute, Minneapolis, Minnesota, USA.
Pharmacoepidemiol Drug Saf. 2023 Oct;32(10):1113-1120. doi: 10.1002/pds.5643. Epub 2023 Jun 8.
Using a novel, electronic health record (EHR)-based approach, to estimate the prevalence of prescription medication use at 2, 4, and 6 months postpartum among lactating individuals.
We utilized automated EHR data from a US health system that records infant feeding information at well-child visits. We linked mothers who received prenatal care to their infants born May 2018-June 2019, and we required infants to have ≥1 well-child visit between 31 and 90 days of life (i.e., 2-month well-child visit with a ±1 month window). Mothers were classified as lactating at the 2-month well-child visit if their infant received breast milk at the 2-month well-child visit. For subsequent well-child visits at 4 and 6 months, mothers were considered lactating if their infant was still receiving breast milk.
We identified 6013 mothers meeting inclusion criteria, and 4158 (69.2%) were classified as lactating at the 2-month well-child visit. Among those classified as lactating, the most common medication classes dispensed around the 2-month well-child visit were oral progestin contraceptives (19.1%), selective serotonin reuptake inhibitors (8.8%), first generation cephalosporins (4.3%), thyroid hormones (3.5%), nonsteroidal anti-inflammatory agents (3.4%), penicillinase-resistant penicillins (3.1%), topical corticosteroids (2.9%), and oral imidazole-related antifungals (2.0%). The most common medication classes were similar around the 4 and 6-month well-child visits although prevalence estimates were often lower.
Progestin-only contraceptives, antidepressants, and antibiotics were the most dispensed medications among lactating mothers. With routine collection of breastfeeding information, mother-infant linked EHR data may overcome limitations in previous studies of medication utilization during lactation. These data should be considered for studies of medication safety during lactation given the need for human safety data.
利用一种新颖的电子健康记录(EHR)方法,估计在产后 2、4 和 6 个月期间哺乳期个体使用处方药物的流行率。
我们利用美国医疗系统的自动 EHR 数据,该数据记录了婴儿在常规儿童就诊时的喂养信息。我们将接受产前护理的母亲与其在 2018 年 5 月至 2019 年 6 月期间出生的婴儿联系起来,并要求婴儿在生命的第 31 至 90 天(即 2 个月大的常规儿童就诊,±1 个月的窗口)之间至少有 1 次常规儿童就诊。如果婴儿在 2 个月大的常规儿童就诊时接受了母乳,那么母亲将被归类为哺乳期。对于 4 个月和 6 个月的后续常规儿童就诊,如果婴儿仍在接受母乳喂养,那么母亲将被认为是哺乳期。
我们确定了 6013 名符合纳入标准的母亲,其中 4158 名(69.2%)在 2 个月大的常规儿童就诊时被归类为哺乳期。在被归类为哺乳期的母亲中,在 2 个月大的常规儿童就诊时开具的最常见药物类别是口服孕激素避孕药(19.1%)、选择性 5-羟色胺再摄取抑制剂(8.8%)、第一代头孢菌素(4.3%)、甲状腺激素(3.5%)、非甾体抗炎药(3.4%)、耐青霉素酶青霉素(3.1%)、局部皮质类固醇(2.9%)和口服咪唑类抗真菌药(2.0%)。在 4 个月和 6 个月的常规儿童就诊时,最常见的药物类别相似,尽管流行率估计值通常较低。
仅孕激素避孕药、抗抑郁药和抗生素是哺乳期母亲最常开的药物。通过常规收集母乳喂养信息,母婴链接的 EHR 数据可能会克服以前关于哺乳期药物使用研究的局限性。鉴于需要人体安全数据,这些数据应考虑用于哺乳期药物安全性的研究。